SCHEMBL4012966

SCHEMBL4012966

CCCCOC(=O)N1CCC(COS(=O)(=O)c2ccc(C)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 1/20 0.50
KMT2A Q03164 1/20 0.47
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GRIN2B Q13224 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
PKM P14618 1/20 0.44
F2 P00734 1/20 0.43
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25199281 0.94 ALDH1A1 (0.46) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL10385453 0.91 ALDH1A1 (0.58) ALDH1A1KDM4EKMT2ANPSR1TP53
SCHEMBL6408846 0.90 ALDH1A1 (0.49) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL30058727 0.89 KMT2A (0.44) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL4448525 0.87 ALDH1A1 (0.43) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL16245059 0.85 CYP2D6 (0.55) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL29426713 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL30135960 0.84 MMP13 (0.48) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL23250054 0.83 KMT2A (0.46) ALDH1A1KDM4EKMT2ACHRM2CHRM1
SCHEMBL3663436 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EKMT2ANPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed
EP-2073806-A2 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-07-01 EP disclosed
WO-2008060789-A2 USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 ALDH1A1 3531/4885KDM4E 1629/4885KMT2A 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.